Cameron and Tyler Winklevoss have filed an S-1 registration with the SEC to launch a spot Zcash ETF that would hold the ZEC cryptocurrency directly and trade on Nasdaq under the ticker 'WINK'. The ETF aims to provide investors exposure to Zcash through traditional brokerage accounts, with Gemini acting as custodian and Winklevoss Capital Fund showing non-binding interest to buy up to $100 million in shares. This move comes amid a resurgence in Zcash's popularity, driven by growing privacy concerns and institutional interest, following similar launches by Grayscale and 21Shares. The filing acknowledges risks including ZEC's volatility and past technical vulnerabilities, and awaits SEC approval before trading can begin.
The Winklevoss twins' proposed Zcash ETF filing is presented here with Pluang's cryptocurrency market context as of Oct 07, 2026 01:12 WIB: Among 50 major cryptocurrencies on Pluang, 24 rose and 25 fell today. Notable price moves include SAND at Rp1.170 with a 3.16% decline and a typical hold time of 123 days, ADA at Rp4.877 up 2.93% with a 126-day hold, and CRV at Rp6.488 down 2.64% with a 62-day hold. Pluang order activity shows a majority selling trend for SAND and ADA, while CRV has a more balanced sell/buy split.
Stryker experienced an 8.8% stock drop on September 8, 2026, wiping out over $10 billion in market value due to ongoing manufacturing problems that were thought resolved. Truist Financial lowered its price target from $340 to $310, reflecting concern...
Bank OZK is scheduled to release its Q3 2026 earnings after market close on October 20, providing investors with updated financial results to compare against Citigroup's current Sell rating. The bank's latest balance sheet shows $41.70 billion in tot...
Scotiabank has increased its price target for Pfizer stock from $30.00 to $33.00, suggesting a potential upside of 20.9% from the current trading price of $27.31. Pfizer, a major pharmaceutical company, holds a strong buy rating with a Zacks Rank of ...
Citigroup has raised its price target for AstraZeneca to £186.00 from £178.00, maintaining a Buy rating following successful Phase 3 clinical trials. The increase reflects higher peak sales forecasts for drugs tozorakimab and SERENA-6, offsetting the...
An analyst from BMO Capital set a $67 price target for Devon Energy, suggesting a 40% upside from its current share price of around $48. The oil and gas producer has consistently beaten earnings estimates recently, showing strong financial health. Ho...
